116P Any regression of tumor (ART) as an intermediate endpoint in patients (pts) treated with immune checkpoint inhibitors (ICI): A pan-cancer analysis. - El Zarif, T.; Pond, G.; Nassar, A.; Adib, E.; Freeman, D.; Thomas, J.; Kalluri, U.; Matar, A.; Kelly, E.; Curran, C.; Kadamkulam Syriac, A.; McClure, H.; et al. (Annals of Oncology, 2022)